Literature DB >> 1437997

Sterile filtration of a parenteral emulsion.

D M Lidgate1, T Trattner, R M Shultz, R Maskiewicz.   

Abstract

The Syntex adjuvant formulation (SAF) containing [thr1]-muramyldipeptide in an oil-in-water emulsion has proven to be an effective adjuvant eliciting both cell-mediated and humoral immune response. As a parenteral emulsion, sterility of the final product was a concern, and various methods of achieving sterility were considered. For emulsions, most conventional sterilization methods are not viable, requiring the more cumbersome technique of sterilizing individual components and assembling/manufacturing under sterile conditions. Emulsion vehicles were manufactured with various models in the Microfluidizer M110 series. All equipment examined was capable of reducing the average dispersed oil droplet size to approximately 160 nm, with varying size ranges. Operating at an internal equipment pressure of greater than 16,000 psi, with at least five cycles through the interaction chamber, the resulting emulsion had a narrow droplet size range distribution, with the largest droplets being small enough to enable sterile filtration. Under specific-manufacturing conditions, the adjuvant emulsion becomes easily filtered through a 0.22-micron cartridge filter, thus yielding a sterile end product. This is the first published example of emulsion sterilization being achieved by terminal filtration.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1437997     DOI: 10.1023/a:1015836512890

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  12 in total

Review 1.  Parenteral emulsions as drug carrier systems.

Authors:  M Singh; L J Ravin
Journal:  J Parenter Sci Technol       Date:  1986 Jan-Feb

2.  Formulation of vaccine adjuvant muramyldipeptides. 3. Processing optimization, characterization, and bioactivity of an emulsion vehicle.

Authors:  D M Lidgate; R C Fu; N E Byars; L C Foster; J S Fleitman
Journal:  Pharm Res       Date:  1989-09       Impact factor: 4.200

3.  The preparation and properties of sterile intravenous emulsions.

Authors:  P K Hansrani; S S Davis; M J Groves
Journal:  J Parenter Sci Technol       Date:  1983 Jul-Aug

4.  The adjuvant activity of nonionic block polymer surfactants. I. The role of hydrophile-lipophile balance.

Authors:  R Hunter; F Strickland; F Kézdy
Journal:  J Immunol       Date:  1981-09       Impact factor: 5.422

5.  A formalin-inactivated whole SIV vaccine confers protection in macaques.

Authors:  M Murphey-Corb; L N Martin; B Davison-Fairburn; R C Montelaro; M Miller; M West; S Ohkawa; G B Baskin; J Y Zhang; S D Putney
Journal:  Science       Date:  1989-12-08       Impact factor: 47.728

6.  Validation of a first-generation Epstein-Barr virus vaccine preparation suitable for human use.

Authors:  A J Morgan; A C Allison; S Finerty; F T Scullion; N E Byars; M A Epstein
Journal:  J Med Virol       Date:  1989-09       Impact factor: 2.327

Review 7.  An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity.

Authors:  A C Allison; N E Byars
Journal:  J Immunol Methods       Date:  1986-12-24       Impact factor: 2.303

8.  The adjuvant activity of nonionic block polymer surfactants. III. Characterization of selected biologically active surfaces.

Authors:  R L Hunter; B Bennett
Journal:  Scand J Immunol       Date:  1986-03       Impact factor: 3.487

9.  Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity.

Authors:  M J Campbell; L Esserman; N E Byars; A C Allison; R Levy
Journal:  J Immunol       Date:  1990-08-01       Impact factor: 5.422

10.  The adjuvant activity of nonionic block polymer surfactants. II. Antibody formation and inflammation related to the structure of triblock and octablock copolymers.

Authors:  R L Hunter; B Bennett
Journal:  J Immunol       Date:  1984-12       Impact factor: 5.422

View more
  3 in total

1.  A cationic lipid emulsion/DNA complex as a physically stable and serum-resistant gene delivery system.

Authors:  S W Yi; T Y Yune; T W Kim; H Chung; Y W Choi; I C Kwon; E B Lee; S Y Jeong
Journal:  Pharm Res       Date:  2000-03       Impact factor: 4.200

2.  Formulation development and antitumor activity of a filter-sterilizable emulsion of paclitaxel.

Authors:  P P Constantinides; K J Lambert; A K Tustian; B Schneider; S Lalji; W Ma; B Wentzel; D Kessler; D Worah; S C Quay
Journal:  Pharm Res       Date:  2000-02       Impact factor: 4.200

Review 3.  Squalene emulsions for parenteral vaccine and drug delivery.

Authors:  Christopher B Fox
Journal:  Molecules       Date:  2009-09-01       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.